The aromatic amino acid sensor GPR142 controls metabolism through balanced regulation of pancreatic and gut hormones. by Rudenko, Olga et al.
Original ArticleThe aromatic amino acid sensor GPR142 controls
metabolism through balanced regulation of
pancreatic and gut hormonesOlga Rudenko 1,2, Jin Shang 3, Alexander Munk 4, Jeppe P. Ekberg 1, Natalia Petersen 1, Maja S. Engelstoft 1,2,
Kristoffer L. Egerod 1,2, Siv A. Hjorth 1, Margaret Wu 3, Yue Feng 3, Yun-Ping Zhou 3, Jacek Mokrosinski 1,2,
Peter Thams 7, Frank Reimann 6, Fiona Gribble 6, Jens F. Rehfeld 8, Jens J. Holst 5,7, Jonas T. Treebak 4,
Andrew D. Howard 3, Thue W. Schwartz 1,2,*ABSTRACT
Objectives: GPR142, which is highly expressed in pancreatic islets, has recently been deorphanized as a receptor for aromatic amino acids;
however, its physiological role and pharmacological potential is unclear.
Methods and results: We ﬁnd that GPR142 is expressed not only in b- but also in a-cells of the islets as well as in enteroendocrine cells, and
we conﬁrm that GPR142 is a highly selective sensor of essential aromatic amino acids, in particular Trp and oligopeptides with N-terminal Trp.
GPR142 knock-out mice displayed a very limited metabolic phenotype but demonstrated that L-Trp induced secretion of pancreatic and gut
hormones is mediated through GPR142 but that the receptor is not required for protein-induced hormone secretion. A synthetic GPR142 agonist
stimulated insulin and glucagon as well as GIP, CCK, and GLP-1 secretion. In particular, GIP secretion was sensitive to oral administration of the
GPR142 agonist an effect which in contrast to the other hormones was blocked by protein load. Oral administration of the GPR142 agonist
increased [3H]-2-deoxyglucose uptake in muscle and fat depots mediated through insulin action while it lowered liver glycogen conceivably
mediated through glucagon, and, consequently, it did not lower total blood glucose. Nevertheless, acute administration of the GPR142 agonist
strongly improved oral glucose tolerance in both lean and obese mice as well as Zucker fatty rat. Six weeks in-feed chronic treatment with the
GPR142 agonist did not affect body weight in DIO mice, but increased energy expenditure and carbohydrate utilization, lowered basal glucose,
and improved insulin sensitivity.
Conclusions: GPR142 functions as a sensor of aromatic amino acids, controlling GIP but also CCK and GLP-1 as well as insulin and glucagon in
the pancreas. GPR142 agonists could have novel interesting potential in modifying metabolism through a balanced action of gut hormones as well
as both insulin and glucagon.
 2018 Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Keywords G-protein-coupled receptor; GPR142; Trp; Glucose homeostasis; Amino acid sensing1. INTRODUCTION
In the academic world, GPR142 has remained a rather overlooked
orphan receptor since it was cloned in 2006 [1], although a
comprehensive proﬁling of G protein coupled receptor (GPCR)
expression [2] by Regard and coworkers identiﬁed early on that it
was highly and almost exclusively expressed in the islets of the
pancreas, and it was also shown to be associated with an obese
phenotype upon knock down in zebraﬁsh [3]. In the pharmaceutical
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of potent, efﬁcacious, synthetic GPR142 agonists that could stim-
ulate insulin secretion and thereby improve glucose tolerance in
mice and even monkeys [4e7]. Nevertheless, in view of the success
of highly efﬁcacious GLP-1 mimetics, which display a series of
additional beneﬁcial effects including improved cardiovascular
outcome, which also is the case for SGLT-2 inhibitors, the phar-
maceutical industry lost interest in targets such as GPR142, which
apparently only provided glucose-dependent insulin secretagogue
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Abbreviations
AUC Area under curve
BAT Brown adipose tissue
CCK Cholecystokinin
CHO Chinese hamster ovary cells
EDL Extensor digitorum longus
eWAT Epididymal white adipose tissue
FACS Fluorescence-activated cell sorting
GIP Gastric inhibitory polypeptide
GI Gastrointestinal
GIPRKO GIP receptor knockout mice
GLP-1 Glucagon-like peptide 1
GPCR G protein-coupled receptor
ITT Insulin tolerance test
KRB KrebseRinger bicarbonate
OGTT Oral glucose tolerance test
qPCR Quantitative polymerase chain reaction
RER Respiratory exchange ratio
SOL Soleus
sWAT Subcutaneous white adipose tissue
TA Tibialis anterior
tGIP Total gastric inhibitory polypeptide
tGLP-1 Total glucagon-like peptide 1
Original ArticleNevertheless, our knowledge about GPR142, its physiological role and
its pharmacological potential, is very limited. In 2012, the Amgen
group described phenylalanine-related synthetic agonists for GPR142
as pharmacological tool compounds, and noted that aromatic amino
acids acted as agonist for the receptor [4]. In 2016, Lin and co-workers
conﬁrmed this and demonstrated that GPR142 agonists could stimu-
late not only insulin but also the secretion of intestinal incretin hor-
mones [8]. Very recently, the same group from Eli Lilly proposed that
the effect of GPR142 on insulin secretion is mediated by the a-cells of
the pancreatic islets and that treatment of islets with GPR142 agonists
for several days increased the ability of a-cells to store and secrete
GLP-1 [9]. Importantly, the GPR142 agonist also increased b-cell
proliferation, which they interpreted to be an indirect effect mediated
through local production of GLP-1 in the islets.
Originally [10], we decided to study GPR142 expression and function
rather broadly in an unbiased manner mainly using the synthetic
GPR142 agonist C-22 as a pharmacologic tool [5]. This compound was
shown to have good oral bioavailability although a relatively fast
plasma clearance [7]. We focused on effects on gut and pancreatic
hormones and studied positive interactions of GPR142 agonism with
dietary intake of glucose and protein. We discovered that GPR142
efﬁciently stimulated pancreatic glucagon secretion, as also recently
described [9], and we found that the effect of GPR142 agonism on
glucose disposal is a balance between insulin-mediated glucose up-
take in fat and muscle and glucagon-mediated glucose production in
the liver. Here we present the results from those acute studies using
the synthetic GPR142 agonist, and we describe the metabolic
phenotype of GPR142 deﬁcient mice as well as the effects of chronic
treatment of diet induced obese (DIO) mice with the GPR142 agonist.
We ﬁnd that, surprisingly, GPR142 agonism also increases energy
expenditure and improves insulin sensitivity.
2. MATERIAL AND METHODS
2.1. Compounds
Amino acids were purchased from SigmaeAldrich (St. Louis, MO). The
GPR142 agonists C-I and C-22 [5] were synthesized by Wuxi AppTec
Inc (Shanghai, China).
2.2. Animals
All animal studies were approved by the Danish Animal Experiments
Inspectorate. Male C57BL/6NTac wild type and GIPereceptor knockout
(GIPRKO), GPR142 knockout (GPR142KO) and GIP-Venus, Glu-Venus
transgenic mice were used in this study. In addition, several separate
cohorts of C57BL/6NTac mice that were used for compound testing
were purchased from Taconic (Denmark). GIP-Venus and Glu-Venus50 MOLECULAR METABOLISM 19 (2019) 49e64  2018 Published by Elsevier GmbH. This isreporter mice have been previously described [11,12]. All mice were
kept and bred at the Department of Experimental Medicine at
Copenhagen University (except for GIP-Venus reporter mice that were
bred at Cambridge Institute for Metabolic Science). All mice were
provided with food and water ad libitum and maintained on a 12-h
light/dark cycle. DIO mice were generated by placing C57BL/6NTac
(Taconic, Denmark) mice on high fat diet (D12492, Research
Diets, NJ, USA) including 60 kcal% from fat, 20 kcal% from
carbohydrates starting at 8 weeks of age. The DIO mice were 35e40
weeks of age at the time of the experiment.
7-week-old male Zucker fatty rats (Charles River Laboratories, MA)
were fed on chow diet (D5008, Research Diets, NJ, USA) and water ad
libitum and maintained on a 12-h light/dark cycle.
2.3. GPR142 knockout mouse generation
The gene-targeting vector for generation of a GPR142 knockout line
was created through replacement of a 73 base-pair fragment (50 TGG
CAC TGG CCC GTC TTG CTG CCA GGA CCA GGA AAC CCT CCT ATC ACT
ATC TCC TGG CAC TCA CGG CTT CAG AT-30) of the coding sequence of
mouse GPR142 within exon 3 with a lacZ-Neo-stop codon cassette,
resulting in the deletion of transmembrane domains 2e7 of the
GPR142 protein. The germ knockout line was backcrossed to C57BL/
6NTac for 8 generations. Mouse genotyping was performed by PCR of
genomic DNA with the following oligonucleotides: 50- AAC GTC CTG
ACT TCA GTG GCA CTG G-30; 50- AAC GTC CTG ACT TCA GTG GCA CTG
G-30; 50- GGG CCA GCT CAT TCC TCC CAC TCA T-30. The PCR products
consisted in fragments of 249 bp (wild type allele) and 449 bp
(knockout allele).
2.4. Generation of GPR142 stable cell lines and inositol phosphate
accumulation assay
Mouse GPR142 was RACE cloned from mouse cDNA libraries. Induc-
ible stable cell line was generated in Chinese hamster ovary (CHO) cells
using the GeneSwitch mifepristone-regulated expression system ac-
cording to the manufacturer’s instruction (Life Technologies, NY, USA).
Cells were plated into poly-D-lysine-coated 96-well plates (20,000
cells/well) and incubated overnight at 37 C with 2 nM Mifepristone to
induce GPR142 expression. The following day cells were incubated
with 0.5 mCi/ml myo[3H]inositol (Perkin Elmer) in 100 mL growth
medium. 24 h after, IP accumulation assay were performed as
described earlier [13].
2.5. Gene expression analysis
Human total RNA was obtained from Invitrogen (CA, USA). Mouse total
RNA was isolated from tissues collected from C57Bl/6NTac mice
(Taconic, NY, USA). Fluorogenic Taqman probes for GPR142 werean open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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purchased from Applied BioSystems (CA, USA). Relative expression
levels of GPR142 were determined by real-time quantitative PCR using
the ABI PRISM 7900 Sequence Detection System from Applied Bio-
Systems (CA, USA) and normalized to beta-actin mRNA levels.
2.6. Single-cell suspension and FACS puriﬁcation
Mouse a- and d-cells were FACsorted from GLU-Venus and Sst-
CrexEYFP derived islets, respectively, while b-cells were co-isolated
based on their bigger size identiﬁed by the forward and side scatter
signal, as described previously [14]. RNA was isolated and processed
using the Ovation Rapid DR Library System (NuGEN) and sequenced
using an Illumina HiSeq 2500 system at the Genomics Core Facility,
Cancer Research UK Cambridge Institute (Cambridge, UK), as
described previously [14].
Single cell suspensions from the small intestine of GIP-Venus or Glu-
Venus mice were prepared and separated into ﬂuorescence-positive
and ﬂuorescence-negative pools of cells using ﬂuorescence-activated
cell sorting (FACS) as described [15]. The cells were sorted directly
into lysis buffer (Ambion, Thermo Fisher Scientiﬁc, Waltham, MA, USA)
and the RNA was puriﬁed using the RNAqueous-Micro RNA isolation kit
(Ambion, Thermo Fisher Scientiﬁc, Waltham, MA, USA). cDNA was
prepared using Superscript III (Invitrogen, Thermo Fisher Scientiﬁc,
Waltham, MA, USA). The expression of 379 G protein-coupled receptors
was tested using custom-designed 384 well qPCR plates from Bar
Harbor BioTechnology. Primer target sequences have been published
before [16]. A genomic DNA sample was used as a calibrator and
relative copy numbers were calculated as described [16].
2.7. Insulin and glucagon secretion assay in isolated islets
Islets were isolated from C57Bl/6NTac mice (Taconic, Denmark) with
liberase digestion and allowed to recover overnight in RPMI 1640
medium with 10% FBS, penicillinestreptomycin, and 11 mmol/L
glucose. Islet perifusion method was described previously [17]. Human
islets were acquired from the Islet Transplant Center (University of
Chicago, Chicago, IL). After culturing overnight in RPMI 1640 medium
with 11 mM glucose, isolated islets were pre-incubated at 37 C in
freshly prepared KrebseRinger Bicarbonate (KRB) buffer without
glucose for 2 h followed by another 2 h of incubation in KRB buffer with
2 or 16 mM glucose. For glucagon secretion, batches of 10 isolated
islets were equilibrated in KRB buffer at 2 mmol/L glucose for 45 min
at 37 C and then transitioned in medium with presence or absence of
C22. Glucose was increased in a stepwise manner. Supernatants were
collected and assayed for hormone content.
2.8. GLP-1 secretion from primary ileal organoids
Mouse ileal organoids were established as previously described
[18,19]. For GLP-1 secretion experiments, 15 mL of Matrigel/orga-
noid suspension was transferred into each well of 96 well plates. 48
h following seeding, organoids cultures were washed with DMEM/
F12 supplemented with 2 mM L-glutamine and 10 mM HEPES and
incubated in 30 mL of the same medium with either 1% DMSO
(vehicle) or with test compounds during 2 h at 37 C. Medium was
collected and spun at 300 g for 2 min at 4 C, transferred to fresh
tubes, and assayed for hormone content. After the experiment, the
DNA content in the wells was measured using DNA Quantitation Kit
Fluorescence Assay (Sigma) according to the manufacturer’s in-
structions. Experiment was repeated 3 times with 3e6 replicates
per series. GLP-1 levels were measured with Total GLP-1 kit
(MesoScale Discovery, MD, USA, cat. no. K150JVC). GLP-1 values
from each well were normalized to the DNA content. The mean value
obtained from the vehicle wells in each experiment was taken as aMOLECULAR METABOLISM 19 (2019) 49e64  2018 Published by Elsevier GmbH. This is an open acces
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fold to the vehicle.
2.9. Treatment and hormone measurements
Mice were gavaged with indicated doses of compounds or vehicle (sterile
water) in 10 ml/kg volumes, according to body weight. Blood was
collected from mice at indicated times either by orbital bleeding in
conscious mice or from the necks of mice immediately after decapita-
tion. Blood samples were collected in tubes containing EDTA, DPPIV and
Aprotinin (Sigma). Samples were centrifuged at 3,500 g for 10 min at
4 C; then, supernatants were transferred into separate tubes. Enzymatic
assay kits were used for determination of plasma insulin and total GLP-1
(MesoScale Discovery, MD, USA; cat. no. K152BZC and K150JVC),
glucagon (Mercodia, Sweden; cat. no. 10-1281-01), total GIP (Millipore,
MA, USA; cat. no. EZRMGIP-55K), respectively. CCK was measured using
speciﬁc radioimmunoassays as described previously [20].
To measure tissues hormone content, a fragment of tissue was ho-
mogenized in acid-ethanol (1.5% HCl in 70% EtOH) and extracted
overnight at 20 C. The solution was centrifuged to remove unho-
mogenized tissue and neutralized. Hormone concentrations in extracts
were determined as described above.
2.10. Gastric emptying
Gastric emptying was assessed by the acetaminophen absorption.
Vehicle, 2 g/kg whey protein alone, C-22 (30 mg/kg) alone or in
combination was co-administered orally with 100 mg/kg acetamino-
phen (SigmaeAldrich) to overnight fasted mice. Blood samples were
drawn from the retro-orbital sinus at 15, 30, and 60 min after
administration. Plasma was prepared as described above and acet-
aminophen concentrations were determined using an acetaminophen
kit with colorimetric detection (MULTIGENT, B2K996; Abbott Labora-
tories). Gastric emptying by phenol red method was performed as
described previously [21].
2.11. Metabolic cages
Whole-body metabolic states were tested by indirect calorimetry in TSE
metabolic cages (LabMaster, TSE Systems, Germany). After a 4-day
habituation, oxygen consumption, CO2 production, energy expenditure,
food and water intake, and spontaneous locomotor activity were
measured simultaneously and continuously for 3 days in housing cages
utilizing an indirect open circuit calorimetry system with an infrared
photo beams. Glucose oxidation in g/min/kg ¼ [(4.545 
VCO2)  (3.205  VO2)]/1000 was calculated as described [22].
2.12. Glucose and insulin tolerance tests
Oral glucose tolerance tests (OGTT) were performed as described
before [17]. For test, mice were fasted overnight (DIO mice for 6 h),
after which 2 g/kg (for DIO mice 1 g/kg) glucose solution was
administered orally at a volume of 10 ml/kg. For compound testing,
mice received either vehicle or compound C-22 30 min prior glucose
loading by oral gavage. Blood glucose was measured from tail blood
with a OneTouch Ultra glucometer (LifeScan, CA, USA) at 15, 30, 60,
and 120 min. For OGTT in male Zucker fatty rats, glucose was
administered at 3 g/kg. Insulin tolerance tests (ITT) were conducted as
described before [17], 6 h fasted mice, were given an i.p. injection of 1
U/kg regular human insulin (Novo Nordisk, Denmark). Blood glucose
levels were measured as described above.
2.13. Glucose uptake
Mice were fasted for four hours starting at the beginning of light phase.
The mice were then gavaged with C-22 (30 mg/kg) and subsequentlys article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 51
Original Articleanesthetized with pentobarbital (80 mg/kg body weight). 15 min later,
before the assay was initiated, the pain reﬂex was tested and tail tip
was cut off. Blood glucose levels were measured with a OneTouch
Ultra glucometer (LifeScan, CA, USA) and a blood sample (40 ml) was
taken as baseline. At time 0, the mice were injected retro-orbitally with
a bolus of [3H] 2-deoxyglucose ([3H]2-DG; 0.3335 mCi/kg). Samples
were again taken at 5, 10, 15, 20, 30, and 40 min, after which mice
were euthanized by cervical dislocation and various tissues, were
dissected and instantly frozen in liquid nitrogen and stored at 80 C
until future analysis. Blood and tissue samples processing were per-
formed as described earlier [23,24].
2.14. Western-blot analysis
Western blot analyses were performed as previously described [23]
using the following antibodies (all were from Cell Signaling Technol-
ogy): phospho- Akt (Ser473) (#9271, 1:1,000), phospho- GSK-3b(Ser9)
(#9336, 1:1,000), phospho-GS(Ser641) (#3891, 1:1,000). Total protein
content, AKT (#9272, 1:1,000), GSK3b (#9315, 1:1,000), GS (#3886,
1:1,000) were used to normalize phosphorylated proteins. GAPDH
(#3683, 1:1,000) was used as an internal loading control.
2.15. Chronic treatment with C-22 mixed into high fat diet
The experiment was performed in single-housed DIO mice (27 weeks
of HFD) habituated to single housing for two weeks. Vehicle or treat-
ment (C-22, at dose 600 or 2,000 mg/kg food) were homogeneously
blended into high fat diet (D12492, Research Diets, NJ, USA) and
grounded into pellets, which were stored at 20 until use. To insure
absence of aversive effects the animals, food intake and body weight
were monitored daily and compared to individual baselines measured
prior to the experiment (Suppl. Figure 7a,b). During initial food habit-
uation, the animal group with C22 at dose 2000 mg/kg food demon-
strated transiently, signiﬁcantly reduced food intake (Suppl. Figure 6a),
probably as result of taste aversion. The weight loss observed in this
group (Suppl. Figure 7b) could confound further result interpretation;
therefore, this group was terminated. C-22 in dose 600 mg/kg food
was well tolerated with no visible aversive effect on food intake. All
mice continued on the treatment diet for the 6-week study. After 2.5
weeks of treatment, mice were habituated to metabolic cages for 4
days. Whole-body metabolic states were then tested in TSE metabolic
cages (LabMaster, TSE Systems, Germany) continuously for 3 days.
OGTT was conducted after 4.5 weeks of treatment. Prior to OGTT mice
were fasted for 6 h and fasting glucose and fasting insulin were
measured. ITT were performed after 5.5 weeks treatment in 6 h fasted
animals. Mice were given an i.p. injection of 1U/kg regular human
insulin (Novo Nordisk, Denmark). Blood glucose levels during OGTT
and ITT were measured as described above.
2.16. Statistical analysis
Statistical analyses were conducted in Prism (Version 4.0.3, Graphpad,
CA, USA) either by one- or two-way analysis of variance (ANOVA)
followed by Sidak’s post hoc test and Student’s t-test as appropriate.
Statistical signiﬁcance was deﬁned as two-tailed p < 0.05.
3. RESULTS
3.1. GPR142 is expressed mainly in pancreatic islet and
enteroendocrine cells
In agreement with the original report [2], we observed that, in both
humans and mice, GPR142 is expressed orders of magnitude higher in52 MOLECULAR METABOLISM 19 (2019) 49e64  2018 Published by Elsevier GmbH. This ispancreatic islets as compared to any other tissue tested (Figure 1A;
and Supp. Figure 1). Originally, it was believed that GPR142 mainly
was involved in b-cell function [5,7]; however, as shown in Figure 1B,
GPR142 expression is higher in glucagon storing a-cell and in so-
matostatin storing d-cells than in the b-cells, which is in agreement
with recent single cell analysis of islets cells [25] and recent in situ
hybridization data [9]. Low level GPR142 expression could be detected
also in the GI-tract (Figure 1A), and qPCR analysis of FACS-puriﬁed
GIP-Venus positive cells from Gip-Venus reporter mice revealed that
although GPR142 was not that highly expressed it was one of the most
highly enriched (68efold) GPCRs in GIP cells (Figure 1C). Similar
analysis of GLP-1 cells in different segments of the small intestine
using the proglucagon (GCG), Glu-Venus reporter mice demonstrated
that GPR142 was only enriched in the jejunum, not in the duodenum or
the ileum (Figure 1D). In fact, GPR142 was expressed at close to
background levels in GLP-1 cells of the ileum. In contrast, the
expression of GPR142 was 50e100-fold higher in pancreatic Glu-
Venus positive cells, i.e. a-cells, compared with Glu-Venus positive
cells (i.e. L-cells) of the GI-tract (Figure 1D).
3.2. GPR142 is a highly selective receptor for aromatic amino
acids e in particular Trp
When tested against all 20 natural L-amino acids, GPR142 proved to
be extremely selective for the aromatic amino acids, as judged by the
ability of L-Trp and L-Phe and with lower efﬁcacy L-Tyr but none of
the other natural amino acids to stimulate IP3 accumulation in
GPR142 transfected CHO cells at 20 mM concentrations (Figure 2A).
Dose response experiments revealed that L-Trp had a potency of
0.18 mM on GPR142, which was approximately 10-fold more potent
than L-Phe (Figure 2B). Interestingly, certain di- and tri-peptides with
N-terminal Trp also acted as agonists on GPR142 (Figure 2C). Thus,
the di-peptide Trp-Tyr apparently had a potency like free L-Trp,
whereas, for example Trp-Val and Trp-His were either less potent or
inactive, respectively. We tested a series of tri-peptides with a Ser
residue in position two to improve solubility. As shown in Figure 2C
(right panel), Trp-Ser-Ser had a potency like the free L-Trp, but a
maximal efﬁcacy of only 25% whereas Ser-Ser-Trp showed limited
activity, indicating the importance of the free a-amino group of Trp
for GPR142 binding. Tri-peptides with Phe or Tyr at the N-terminus
were totally inactive. We also tested a number of derivatives of
tryptophan such as serotonin and melatonin as well as tryptophan
metabolites of the kynurenine pathway, many of which also are
biologically active but all of which failed to activate GPR142 (Supp.
Table 1). Similarly, a number of microbial aromatic metabolites did
not activate GPR142. Only 5-hydroxytryptophan stimulated GPR142,
but with low efﬁcacy and with more than ten-fold lower potency than
L-Trp (Supp. Table 1).
3.3. GPR142 is required for the stimulatory effects of L-Trp but not
protein on hormone secretion
L-Trp is known to stimulate the secretion of not only insulin but also
glucagon and gut hormones [26e28]. In fact, L-Trp potentiated
glucose stimulated insulin secretion from isolated murine islets with an
efﬁcacy almost similar to that of GLP-1 (Figure 2D). In vivo, 500 mg/kg
of L-Trp administered by oral gavage increased plasma levels of in-
sulin, glucagon, GIP and GLP-1 in overnight fasted wild type mice,
although the increase in GLP-1 did not reach statistical signiﬁcance in
these particular experiments (Figure 2E). The very high dose was
based on pilot dose-response experiments and doses used in thean open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 1: Expression of GPR142 in human and mouse tissues. (A) Expression of GPR142 mRNA in human (n ¼ 3) and mouse (n ¼ 3). GI-tract and pancreas assessed by RT-
PCR and normalized to beta-actin. (B) GPR142 expression in FACS-puriﬁed a-, b-, and d-cells from mouse pancreas (see Materials and Methods for details). The data were
derived from n ¼ 5, n ¼ 4 and n ¼ 6 independent a-, b-, and d-cell isolations respectively. (C) Scattergram of the expression of 379 GPCRs in relative copy numbers in GIP-
Venus-positive cells (y-axis) vs expression in GIP-Venus-negative cells (x-axis). The dotted lines indicate 10- and 100-fold enrichment of expression in GIP-positive vs neighboring
cells. In gray is indicated the noise area for the analysis (wcycle threshold ¼ 35). The data were derived from n ¼ 3 independent cell isolations. (D) qPCR analysis (n ¼ 3) of the
GPR142 expression in Glu-Venus positive vs. Glu-Venus negative fraction of sorted cells from segments of the small intestine and from the pancreas. The results are presented as
relative expression to reference genes (average of HPRT, Rn18s and Ywhaz).literature [26]. Importantly, the fact that no hormone response to L-Trp
was observed in GPR142 deﬁcient mice indicate that L-Trp’s effect on
gastrointestinal and pancreatic hormones is mediated through GPR142
(Figure 2E).
Because GPR142 is a sensor of essential aromatic amino acids and
certain oligo-peptides, the receptor could very well be involved also in
the hormone responses to dietary protein intake. However, as shown in
Figure 2F, GPR142 is not required, as the response in both insulin and
glucagon as well as GIP and GLP-1 to an oral protein challenge was
identical in GPR142 deﬁcient mice as in littermate control animals.
3.4. GPR142 deﬁcient mice display no major metabolic phenotype
Regarding overall phenotype, the GPR142 knockout mice exhibited
normal growth with no signiﬁcant difference from littermate con-
trols in body composition, apart from a trend towards increased
lean mass in the GPR142 knockout mice (Supp. Figure 2a). Indirect
calorimetry did not reveal any difference in energy expenditure and
respiratory exchange ratio (RER) and no changes in spontaneous
locomotor activity and food intake (Supp. Figure 2bee). GPR142
knockout mice also had normal response to fasting/re-feeding
challenge in terms of basal metabolic parameters (Supp.
Figure 2bee) and displayed normal insulin responses during oral
glucose tolerance test (OGTT) (Supp. Figure 2f,g). Importantly,
exposure to prolonged high-fat diet did not induce any signiﬁcant
difference in the metabolic phenotype including response in OGTT
and ITT (Supp. Figure 3aeh).MOLECULAR METABOLISM 19 (2019) 49e64  2018 Published by Elsevier GmbH. This is an open acces
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dependent manner and is not blocked by protein intake
To try to understand the role of GPR142 in metabolism in more detail
we turned to pharmacological studies and among the high potency,
efﬁcacious, synthetic agonists for GPR142 [4e7] we chose the potent
(Kd ¼ 22 nM, Figure 2B), orally active compound 22 [5] to initially
focus on effects on pancreatic hormone secretion.
As shown in Figure 3A, the synthetic GPR142 selective agonist stim-
ulated insulin secretion from mouse islets in a highly glucose-
dependent fashion. This was also the case in human islets as here
shown using another GPR142 agonist, C1 (Figure 3B). C22 also
induced insulin secretion from the Min6 mouse b-cell line, which
express endogenous GPR142 receptors (Supp. Figure 4).
In fasting lean mice, oral administration of C-22 increased plasma
levels of insulin in a dose-dependent manner (Figure 3C), which was
not observed in GPR142 deﬁcient mice (Figure 3D). The in vivo insulin
response to the GPR142 agonists was strongly increased when co-
administered with glucose (2 mg/kg) (Figure 3E). As GPR142 is an
amino acid receptor it was possible that an attenuated response to the
synthetic agonist could be observed in the presence of increased levels
of amino acids following an oral protein challenge. However, as shown
in Figure 3F, the incremental insulin response to the GPR142 agonist
was not diminished but in fact signiﬁcantly enhanced when given in
combination with a high oral protein load, which, importantly in these
experiments, by itself increased plasma insulin to the same degree as
C-22 alone (Figure 3F).s article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 53
Figure 2: Identiﬁcation of GPR142 as a sensor of aromatic amino acids and oligopeptides and requirement of GPR142 for the effect of L-Trp but not protein on
hormone secretion in mice. (A) Relative [3H] IP accumulation in mouse GPR142 transfected CHO cells after stimulation with different amino acids (n ¼ 3). Accumulated [3H] IP
was detected with poly-L-lysine-coated Ysi SPA beads. Data are normalized to Emax for TRP (100%) in IP-accumulation. (B) Dose response for C-22, L-Trp and L-Phe in terms of
[3H] IP accumulation in mouse GPR142 transfected CHO cells (n ¼ 3). (C) Relative [3H] IP accumulation after stimulation with different di- and tri-peptides (n ¼ 3). (D) Insulin
secretion from isolated islets (n ¼ 3). Islets were cultured overnight and batches of 5 isolated islets were incubated for 2 h with 2 or 16 mmol/l glucose in the absence or presence
of L-Trp. (E,F) Plasma insulin, glucagon, GIP, GLP-1 levels in overnight fasted wild type and GPR142 deﬁcient mice (n ¼ 6e9 per group) after an oral Trp (500 mg/kg) (E) or protein
(2 g/kg whey protein) (n ¼ 6e8 per group) (F) challenges. Data are presented as mean values  SEM. *p < 0.05, **p < 0.01, ***p < 0.005 vehicle vs C-22 determined by
Student’s unpaired t-test or one-way ANOVA, as appropriate.
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Figure 3: Acute effects of synthetic GPR142 agonist on insulin and glucagon secretion in mice. (A) Representative insulin secretion proﬁle from perifused mouse islets
exposed to step-wise increasing concentrations of glucose in the absence or presence C-22. Automated multichannel perifusion apparatus used (25 islets per channel; n ¼ 3
channels per group; 0.26 ml/min ﬂow rate). The ﬁgure is representative of 3 independent experiments. (B) Insulin secretion from human islets with 2 or 16 mmol/l glucose in the
absence or presence of synthetic GPR142 agonist (CeI) or GLP-1 at indicated concentration. N ¼ 3. (C) Plasma level of insulin in mice (n ¼ 8 in each group) 15 min after an oral
administration of vehicle or C-22 in dose 1, 5 or 30 mg/kg. (D) Plasma level of insulin in wild type and GPR142KO mice (n ¼ 7e8 in each group) orally administered with vehicle or
30 mg/kg C-22; 15 min after administration. (E) Time course of changes in plasma level of insulin in mice (n ¼ 8 in each group) after an oral administration of vehicle, 2 g/kg
glucose alone, 30 mg/kg C-22 alone, or in combination. (F) Plasma level of insulin in mice (n ¼ 6e9 in each group) after an oral administration of vehicle, 2 g/kg whey protein
alone, C-22 (30 mg/kg) alone or in combination. (G) Glucagon secretion from mouse islets exposed to step-wise increasing concentrations of glucose in the absence or presence of
C22. N ¼ 3. (H) Plasma level of glucagon in mice (n ¼ 6 in each group) 15 min after an oral administration of vehicle or C-22 in dose 1, 5 or 30 mg/kg. (I) Plasma level of glucagon
in wild type and GPR142 deﬁcient mice (n ¼ 7e9 in each group) 15 min after an oral administration of vehicle or 30 mg/kg C-22. (J) Time course of changes in plasma glucagon
level in mice (n ¼ 8 in each group) after an oral administration of vehicle, 2 mg/kg glucose alone, C-22 alone or in combination. (K) Plasma level of glucagon in mice (n ¼ 6e9 in
each group) after an oral administration of vehicle, 2 g/kg whey protein alone, C-22 (30 mg/kg) alone or in combination. All data are presented as mean values  SEM. Data in (Ae
D, GeI) *p < 0.05, **p < 0.01, ***p < 0.005 vehicle vs C-22 determined by Student’s unpaired t-test or one-way ANOVA, as appropriate. Data in (E,F,J,K) ***p < 0.005 vehicle vs
C-22; ##p < 0.001 vehicle vs glucose; þ p < 0.05, þþ p < 0.01 C-22 vs C-22 in combination with glucose; && p < 0.01 vehicle vs protein; ¤ p < 0.05 C-22 vs C-22 in
combination with protein determined as two-way ANOVA with Sidak’s post-hoc test.
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Original Article3.6. GPR142 stimulates glucagon secretion, an effect which is not
blocked by protein intake
C-22 stimulated glucagon secretion from isolated murine islets at 2
and 8 mM glucose and numerically also at 16 mM, which did not reach
statistical signiﬁcance (Figure 3G). In lean, fasting mice, oral admin-
istration of the synthetic GPR142 agonist increased plasma glucagon
levels in a dose-dependent manner (Figure 3H), which was not
observed in GPR142 deﬁcient animals (Figure 3I). The rapid, robust
glucagon response to C-22 was diminished signiﬁcantly when co-
administered with oral glucose (Figure 3J). As observed for insulin,
the incremental glucagon response to C-22 was not attenuated but
enhanced by an oral protein load (Figure 3K).
3.7. GIP secretion is very sensitive to oral GPR142 agonist
stimulation which is blocked both by glucose and by protein intake
In the enteroendocrine system, we observed that plasma levels of total
GIP (tGip) were increased strongly in a dose-dependent manner by oral
administration of C-22 (Figure 4A), which was not the case in GPR142
deﬁcient mice (Figure 4B). Interestingly, tGIP was particularly sensitive
to the GPR142 agonist as a dose of only 1 mg/kg induced a signiﬁcant,
large increase in plasma tGIP levels (Figure 4A), which was not
observed for insulin and glucagon, where 5 or 30 mg/kg doses of C-22
were required for signiﬁcant stimulation (Figure 3C,H). This is likely due
to the fact that GIP is expressed mainly in the proximal small intestine
where the orally administered C-22 compound is being absorbed and
that the GIP cells consequently are exposed to relatively high concen-
trations of the compound as compared to cells in the pancreatic islet.
GIP was very strongly stimulated by oral glucose, and, in contrast to
insulin, we did not observe any further increase in GIP levels when C-22
was administered on top of the glucose load (Figure 4C). This lack of
response was not because GIP was maximally stimulated as we also
observed lack of stimulatory effect of C-22 when the GPR142 agonist
was administered on top of a smaller glucose load (Supp. Figure 5).
As expected plasma levels of tGIP were increased signiﬁcantly in
response to the oral protein load (Figure 4D). In these experiments, the
tGIP response to C-22 alone was similar to the response to protein, but,
in contrast to insulin and glucagon, C-22 was not able to stimulate tGIP
further when administered on top of the protein challenge (Figure 4D).
GIP released from the proximal intestine could theoretically be involved
in the GPR142-induced responses of insulin and glucagon as GIP is
known to stimulate the secretion of both of these hormones [29,30].
We addressed this issue by measuring the hormone responses in GIP
receptor (GIPR) deﬁcient mice. As shown in Figure 4E, both insulin and
glucagon responses to the GPR142 agonist were numerically lower in
the GIPR deﬁcient mice as compared to littermate control mice;
however, the differences did not reach statistical signiﬁcance as clear
responses in insulin and glucagon were observed also in the GIP re-
ceptor deﬁcient mice (Figure 4E). Thus, GIP could possibly be
responsible for part of the response of the pancreatic hormones, but
clearly the GPR142 agonist stimulates insulin and glucagon secretion
also independently of GIP, which likely involves direct action on
pancreatic cells.
3.8. GPR142 also stimulates CCK secretion
Like GIP, CCK is mainly expressed in the upper part of the small in-
testine and as shown in Figure 4F, oral administration of the GPR142
agonist C-22 also increased plasma levels of CCK and in a GPR142
dependent manner (Figure 4G). However, in contrast to what was
observed for GIP, C-22 was able to further stimulate CCK in the
presence of protein intake (Figure 4H). Due to the fact that large
amounts of sample material are required for the CCK measurement we56 MOLECULAR METABOLISM 19 (2019) 49e64  2018 Published by Elsevier GmbH. This isdid not prioritize further the characterization of GPR142 effects on CCK
secretion.
3.9. GPR142 increases plasma GLP-1 levels independent on GIP
Although some GLP-1 is expressed in the upper small intestine [31],
the main site of GLP-1 production in the GI-tract is the lower small
intestine and colon [32,33]. In agreement with this, we observed that
C-22 could stimulate tGLP-1 secretion from ileal organoids (Figure 4I)
Oral administration of C-22 increased plasma tGLP-1 levels in a dose-
and GPR142-dependent manner (Figure 4J,K), but the stimulation only
reached signiﬁcance at the highest dose tested, i.e. 30 mg/kg
(Figure 4J), meaning that GLP-1 is less sensitive than insulin and
glucagon in respect of GPR142 stimulation and much less sensitive
than GIP (Figure 4A). When administered on top of the oral glucose
challenge, C-22 was not able to stimulate tGLP-1 more than glucose
alone, whereas the response to C-22 was still observed after 30e
45 min where no response to glucose alone was observed (Figure 4L).
However, when administered on top of the protein challenge the
response to C-22, which alone stimulated tGLP-1 to a similar degree
as the protein, was not blocked by the protein as an almost additive
stimulatory effect was observed (Figure 4M), as also was observed for
CCK, glucagon, and insulin (Figure 3F,K) but not GIP (Figure 4D).
In mice, the stimulatory effect on GLP-1 secretion could in principle be
mediated through GIP [34]; however, as shown in Figure 4N, C-22
stimulated tGLP-1 to the same degree in GIP receptor deﬁcient mice.
3.10. GPR142 delays gastric emptying
As determined both by the acetaminophen absorption method and by
the phenol red method, C-22 decreased gastric emptying in a GPR142-
dependent manner (Figure 5A,B). The effect of the GPR142 agonist
was not blocked by oral protein, which in itself delayed gastric
emptying (Figure 5A).
3.11. GPR142 improves glucose tolerance and increases
carbohydrate oxidation in lean rodents
At this stage it was clear that stimulation of GPR142 resulted in an
increase in plasma levels of a number of pancreatic and gut hormones
with potential complex co-actions on glucose homeostasis and
metabolism in general including gastric emptying. Importantly, as
shown in Figure 5C, the net result of an acute oral administration of the
GPR142 agonist was a substantial GPR142-dependent improvement of
glucose tolerance even in fasting lean animals (Figure 5C).
When tested acutely in lean mice habituated to metabolic cages, oral
administration of the GPR142 agonist did not affect energy expendi-
ture, food intake (Figure 5D,E), or locomotor activity (Supp. Figure 6).
However, during the ﬁrst hour after the oral administration, C-22
induced a signiﬁcant increase in the respiratory exchange ratio (RER) in
wild type mice but not in the littermate GPR142 knockout mice
(Figure 5F). This translated into an increase in glucose oxidation
(Figure 5G), indicating a shift in substrate preference toward carbo-
hydrate oxidation. In these acute experiments, the effect of C-22 was
transient (Figure 5F) conceivably due to the short pharmacokinetic
half-life of the compound. Thus, GPR142 activation apparently leads to
an increase in whole body carbohydrate oxidation.
3.12. GPR142 stimulates glucose uptake in muscle and adipose
tissue and reduces liver glycogen stores in both lean and obese
animals
Although the GPR142 agonist clearly had a beneﬁcial effect on overall
glucose tolerance, the fact that several different ‘counteracting’ glu-
coregulatory hormones potentially could be involved justiﬁed a morean open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 4: Acute effects of synthetic GPR142 agonist C-22 on enteroendocrine hormones in mice. (A) Plasma level of tGIP in mice (n ¼ 6e8 in each group) 15 min after an
oral administration of vehicle or C-22 in dose 1, 5 or 30 mg/kg. (B) Plasma level of tGIP in mice (n ¼ 7e8 in each group) 15 min after an oral administration of vehicle or C-22
(30 mg/kg) in wild type and GPR142 deﬁcient mice. (C) Time course of changes in plasma level of tGIP in mice (n ¼ 8 in each group) after an oral administration of vehicle, 2 g/kg
glucose alone, 30 mg/kg C-22 alone or combination. (D) Time course of changes in level of tGip in mice (n ¼ 6e9 in each group) after an oral administration of vehicle, 2 g/kg
whey protein alone, C-22 (30 mg/kg) alone or in combination. (E) Plasma level of insulin and glucagon in wild type and GipR deﬁcient mice (n ¼ 6e7 per group) orally administered
with vehicle or 30 mg/kg C-22; 15 min after administration. (F) Plasma level of CCK in mice (n ¼ 6e7 in each group) 15 min after an oral administration of vehicle or C-22 in dose
5 or 30 mg/kg. (G) Plasma level of CCK in mice (n ¼ 8 in each group) 15 min after an oral administration of vehicle or C-22 (30 mg/kg) in wild type and GPR142 deﬁcient mice. (H)
Plasma level of CCK in mice (n ¼ 6e8 in each group) 15 min after an oral administration of vehicle, 2 g/kg whey protein alone, C-22 (30 mg/kg) alone or in combination. (I) tGlp-1
secretion (fold to vehicle) in ileal organoids cultures (n ¼ 4) in presence of C22 or vehicle. L-3740, TGR5 receptor agonist was used as positive control. (J) Plasma level of tGLP-1 in
mice (n ¼ 6e8 in each group) 15 min after an oral administration of vehicle or C-22 in dose 1, 5, or 30 mg/kg. (K) Plasma level of tGLP-1 in mice (n ¼ 7e8 in each group) 15 min
after an oral administration of vehicle or C-22 (30 mg/kg) in wild type and GPR142 deﬁcient mice. (L) Time course of changes in plasma level of tGLP-1 i mice (n ¼ 8 in each
group) after an oral administration of vehicle, 2 g/kg glucose alone, 30 mg/kg C-22 alone or combination. (M) Time course of changes in plasma level of tGLP-1 in mice (n ¼ 6e9
in each group) after an oral administration of vehicle, 2 g/kg whey protein alone, C-22 (30 mg/kg) alone or in combination. (N) Plasma level of tGLP-1 in wild type and GipR
deﬁcient mice (n ¼ 6e7 per group) orally administered with vehicle or 30 mg/kg C-22; 15 min after administration. Data in (A,B,E-K,N) *p < 0.05, **p < 0.01, ***p < 0.005
vehicle vs C-22, determined by Student’s unpaired t-test or one-way ANOVA, as appropriate. Data in (C,D,L,M) *p < 0.05, **p < 0.01, ***p < 0.005 vehicle vs C-22; ##p < 0.01,
###p < 0.005 vehicle vs glucose; && p < 0.01, &&& p < 0.005 vehicle vs protein; ¤ p < 0.05 C-22 vs C-22 in combination with protein determined as two-way ANOVA with
Sidak’s post-hoc test.
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Figure 5: Acute effects of synthetic GPR142 agonist on metabolic functions in lean mice. (A, B) Gastric emptying. (A) Time courses of plasma acetaminophen in mice
(n ¼ 7e8 in each group) orally administered with vehicle, 2 g/kg whey protein alone, C-22 (30 mg/kg) alone or in combination. All treatments were mixed with acetaminophen. (B)
Gastric content of phenol red recovered from the stomach of wild type and GPR142 KO mice (n ¼ 5e7 in each group) sacriﬁced 0 or 20 min after oral administration 2 g/kg whey
protein alone or in combination with C22 (30 mg/kg). 100% is mean absorbance of phenol red recovered from the stomachs of wild type mice at 0 min following 2 g/kg whey
protein load. (C) Blood glucose level during OGTT and AUC in wild type and GPR142 deﬁcient mice (n ¼ 8 mice in each group) after an oral administration of vehicle or C-22
(30 mg/kg) followed by 2 g/kg oral glucose challenge. (DeF) Indirect calorimetry measurements of energy expenditure (D), food intake (E), and RER (F) in non-fasted wild type and
GPR142 deﬁcient (n ¼ 8 in each group) mice after oral administration of 30 mg/kg C-22 or vehicle. Signiﬁcant difference indicated on graph was calculated as mean value for 1 h
after treatment. (G) Glucose oxidation was calculated as described [22] for 1 h after treatment. (H) Time course proﬁle of [3H] 2-deoxyglucose speciﬁc blood activity; and (I) blood
glucose concentration after vehicle or C-22 treatment in 4 h fasted anesthetized mice (n ¼ 7e8 in each group). (J) Tissue-speciﬁc glucose uptake in tibialis anterior (TA), extensor
digitorum longus (EDL), soleus (SOL), epididymal (eWAT) and subcutaneous (sWAT) white adipose tissue and brown fat (BAT) in mice (n ¼ 7e8 in each group) over a 40-min period
starting 15 min after C-22 (30 mg/kg) administration. The accumulation of [3H] 2-deoxyglucose-6-phosphate was normalized to tissue weight. (K) Time course proﬁle of plasma
insulin after vehicle or C-22 treatment in 4 h fasted anesthetized mice. (L) Representative western-blot analysis and quantiﬁcation of expression and phosphorylation of AKT, GSK
and GS in TA muscle 55 min after vehicle or C-22 treatment (n ¼ 8 in each group). Data expressed as level of phosphorylated or total form to GAPDH. (M) Liver glycogen content
over a 55-min period after vehicle or C-22 treatment in 4 h fasted anesthetized mice (n ¼ 7e8 in each group). (N) Plasma glucagon concentration 55 min after vehicle or C-22
treatment in 4 h fasted anesthetized mice (n ¼ 7e8 in each group). All data are presented as mean values  SEM. Data in (A,C,D,F,H,I,K) **p < 0.01, ***p < 0.005 vehicle vs C-
22 determined as two-way ANOVA with Sidaks’s post-hoc test. Data in (B) ¤¤ p < 0.01 protein vs protein in combination with C22; (E,G,J,LeN) *p < 0.05, **p < 0.01,
***p < 0.005 vehicle vs C-22 determined by Student’s unpaired t-test or one-way ANOVA, as appropriate.
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detailed analysis of the GPR142-mediated changes in glucose meta-
bolism. As shown in Figure 5H, C-22 potently enhanced the whole-
body clearance of [3H]-2-deoxyglucose while surprisingly not
affecting the blood glucose levels as such (Figure 5I), which would
have been expected if the effect was mediated solely by an insulin
action. The GPR142 agonist induced a considerable accumulation of
[3H]-2DG6P in different types of muscles (Figure 5J). Similarly, C-22
induced increased glucose uptake in both epididymal and subcu-
taneous white fat depots and in inter-scapular brown adipose tissue
(Figure 5J). As the GPR142 agonist in these experiments strongly
stimulated insulin secretion (Figure 5K), it is most likely that the
increased glucose uptake in muscle and adipose is mediated through
insulin, which was supported by the fact that we observed increased
activities in classical insulin signaling pathways in skeletal muscle, i.e.
increased phosphorylation of AKT(Ser473) and increased phosphory-
lation of the AKT substrate glycogen synthase kinase-3b GSK(Ser9),
which decreases its activity and in accordance with the decreased
phosphorylation (increased activity) of glycogen synthase (Figure 5L).
The fact that total blood glucose did not decrease in response to the
GPR142 agonist while the tracer data clearly indicated that glucose
uptake was strongly increased (Figure 5H,I), suggests that glucose
production was increased at the same time. This notion was supported
by the fact that liver glycogen content was decreased by approx. 40%
compared with vehicle-treated mice (Figure 5M); an effect most likely
attributed to the very strong increase in plasma glucagon following the
C-22 treatment (Figure 5N).
3.13. Obese rodents are equally or more susceptible to GPR142
effects on endocrine and metabolic functions
In DIO mice, which as expected had high circulating levels of insulin, C-
22 strongly increased plasma insulin even further in both fasted and
glucose-stimulated animals (Figure 6A). In the fasting DIO mice, the
GPR142 agonist also stimulated glucagon secretion to a similar degree
as in the lean mice (Figure 6A). However after glucose stimulation,
where the glucagon levels in the DIO mice paradoxically were
increased, which has been reported previously in diabetic animals
[35], C-22 administration did not increase glucagon levels further, i.e.
the apparent increase did not reach statistical signiﬁcance (Figure 6A).
Concerning the incretins, acute treatment of DIO mice with C-22
resulted in a signiﬁcant elevation of both tGLP-1 and tGIP (Figure 6A),
i.e. as observed in the lean mice (Figure 4A,J).
In DIO mice, oral administration of the GPR142 agonist lowered basal
blood glucose (from 10.1  0.4 to 7.5  0.3) and improved glucose
tolerance highly signiﬁcantly in a dose-dependent manner with a
maximal effect reached with 5 mg/kg (Figure 6B). Similarly, in Zucker
fatty rats, oral administration of C-22 improved glucose tolerance
dramatically (Figure 6C) while as expected stimulated insulin secretion
(Figure 6D). As observed in the lean mice, C-22 increased the clear-
ance of [3H]-2-deoxyglucose tracer from plasma of DIO mice without
lowering total blood glucose (Figure 6E,F). In fact, blood glucose levels
of C-22 treated DIO mice were slightly but not signiﬁcantly increased
(Figure 6F). As observed in the lean animals, glucose uptake was
increased in various muscle and fat depots of the DIO mice (Figure 6G);
however, the basal glucose uptake was rather high in the EDL muscle
and was not further increased, and the increase in glucose uptake in
the epididymal white fat did not reach statistical signiﬁcance. Impor-
tantly, in the DIO animals we observed a statistically signiﬁcant
decrease in liver glycogen similar to the decrease observed in the lean
animals conceivably due to glucagon-induced glycogenolysis
explaining the lack of drop in blood glucose despite the increased
glucose uptake in muscle and fat (Figure 6H).MOLECULAR METABOLISM 19 (2019) 49e64  2018 Published by Elsevier GmbH. This is an open acces
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agonist increases energy expenditure, decreases basal glucose and
increases insulin sensitivity
The effect of chronic exposure to the GPR142 agonist was studied in
DIO mice which after reaching a body weight of approx. 50 g (27
weeks of HFD) were either continued on the 60% HFD or switched to
HFD containing C-22 at a dose ofw30 mg/kg/day for six weeks. No
effect on body weight (Figure 7A) or body composition (data not shown)
was observed, although the GPR142 treated group did show a non-
signiﬁcant nominal increase in food intake in particular during the
light phase (Figure 7B). However, as revealed by indirect calorimetry,
the C-22-treated mice displayed a clear, signiﬁcant increase in energy
expenditure (Figure 7C), which closely corresponded to the increase in
calorie intake (Figure 7D), which could explain the lack of effect on
body weight. In addition, C-22-treated mice had increased activity
(Figure 7E). Furthermore, as observed in the acutely treated lean an-
imals (Figure 5F), the GPR142 agonist treated mice had e in this case
continued e an increased respiratory exchange ratio during light
phase (Figure 7F), corresponding to an increased carbohydrate utili-
zation, calculated as an increase in glucose oxidation (Figure 7G).
OGTT and insulin tolerance tests (ITT) were both performed after six
hours fasting, which, due to the relatively short T1/2 of the C-22
compound, reﬂects the effect of the long-term treatment with C-22 on
the organism but does not reﬂect direct effects of the compound as it
would no longer be present in therapeutic concentrations in plasma
when these tests were performed (Supp. Figure 7c). As shown in
Figure 7H, six weeks treatment with C-22 signiﬁcantly decreased
fasting glucose (8.77  0.25 versus 7.03  0.28) and there was a
trend toward reduction in fasting insulin level (Figure 7I). However, the
incremental glucose excursions after the oral glucose load were only
marginally decreased in the C-22 treated animals as compared to the
control animals (Figure 7H), and there was no signiﬁcant difference in
glucose AUC (p¼ 0.056). Importantly, the ITT showed (Figure 7J) that,
whereas the DIO mice that were still on normal HFD clearly were very
insulin intolerant, displaying basically no decrease in blood glucose in
response to 1 U/kg insulin i.p., the C-22 treated animals displayed a
clear increase in insulin sensitivity with a signiﬁcant decrease in blood
glucose from 6.8  0.2 to 4.9  0.4 after insulin treatment.
It has recently been reported that GPR142 increased b-cell prolif-
eration and that 96 h treatment with a GPR142 agonist increased
insulin, glucagon and GLP-1 content of isolated islets [9]. However,
we did not observe any increase in pancreatic content of insulin,
glucagon, and total GLP-1 or duodenal content of total GLP-1 in the
DIO mice treated with C-22 for six weeks (Figure 7K,L). On the
contrary, we observed a small insigniﬁcant decrease in the content of
all four hormones.
4. DISCUSSION
In the present study, we conﬁrm that the recently deorphanized receptor
GPR142 is almost exclusively expressed in endocrine cells of the GI-tract
and pancreas and that it functions as a highly selective receptor for ar-
omatic amino acids, in particular Trp. Moreover, we ﬁnd that GPR142
also recognizes small oligopeptides with an N-terminal Trp residue. By
use of the highly selective and potent GPR142 agonist, C-22 we observe
that GPR142 affects a number of metabolic functions in mice conceivably
through its stimulatory effects on enteropancreatic hormones. Impor-
tantly, chronic treatment of DIO mice with the GPR142 agonist improves
metabolic function including insulin sensitivity and energy expenditure.
However, despite these clear indications of a pharmacotherapeutic po-
tential, the actual physiological role of GPR142 is still rather unclear.s article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 59
Figure 6: Acute effects of synthetic GPR142 agonist on hormone secretion, glucose tolerance and glucose uptake in DIO mice and Zucker rats. (A) Plasma insulin,
glucagon, tGip, tGLP-1 levels in DIO mice (n ¼ 7e8 in each group) 15 min after an oral administration of vehicle, 2 g/kg glucose alone, C-22 alone or in combination with 2 g/kg
glucose. Plasma tGLP-1 additionally measured at 30 min after administration. (B) Blood glucose level during OGTT and AUC in mice (n ¼ 7e8 in each group) after an oral
administration of vehicle or C-22 in dose 1, 5 or 30 mg/kg followed by oral glucose challenge (2 g/kg). (C) Plasma glucose and (D) insulin level during OGTT in Zucker fatty rats
(n ¼ 6 in each group) after an oral administration of vehicle or C-22 in dose 30 mg/kg followed by oral glucose challenge (3 g/kg). (E) Time course proﬁle of [3H]2-deoxyglucose
speciﬁc blood activity and (F) blood glucose concentration after vehicle or C-22 treatment in 4 h fasted anesthetized mice (n ¼ 13e14 in each group). (G) Tissue-speciﬁc glucose
uptake in tibialis anterior (TA), extensor digitorum longus (EDL), soleus (SOL), epididymal (eWAT) and subcutaneous (sWAT) white adipose tissue, liver, and brown fat (BAT) in mice
(n ¼ 13e14 in each group) over a 40-min period started 15 min after C-22 (30 mg/kg) administration. The accumulation of [3H] 2-deoxyglucose-6-phosphate was normalized to
tissue weight. (H) Liver glycogen content over a 55-min period after vehicle or C-22 treatment in 4 h fasted anesthetized mice. All data are presented as mean values  SEM. Data
in (A,G,H) *p < 0.05, **p < 0.01, ***p < 0.005 vehicle vs C-22; #p < 0.05, ###p < 0.005 vehicle vs glucose; þþ p < 0.01 C-22 vs C-22 in combination with glucose
determined by Student’s unpaired t test or one-way ANOVA, as appropriate. Data in (BeF) *p < 0.05, **p < 0.01, ***p < 0.005 vehicle vs C-22 determined as two-way ANOVA
with Sidak’s post-hoc test.
Original Article4.1. Effects of GPR142 agonists on entero-pancreatic hormone
secretion
C-22 has good bioavailability [5,7] and was administered orally both in
the acute and chronic studies. We ﬁnd enteroendocrine GIP cells to be
particularly sensitive to GPR142 agonist stimulation as plasma levels of
GIP increased even in response to the lowest dose tested as opposed to
the other gut and pancreatic hormones. This is probably due to the fact
that GIP is stored and released from cells located in the duodenum and
upper small intestine where C-22 likely is absorbed and that GIP cells
consequently are exposed to higher local concentrations of the60 MOLECULAR METABOLISM 19 (2019) 49e64  2018 Published by Elsevier GmbH. This iscompound. Another interesting observation was that both an oral
glucose challenge and an oral protein challenge blocked the ability of the
GPR142 agonist to stimulate GIP secretion further. That was not the case
for the other hormones, as C-22 instead acted in an additive manner, i.e.
it stimulated CCK, GLP-1, insulin and glucagon secretion even further in
combination with protein (discussed below in relation to the physio-
logical role of GPR142 as a dietary protein sensor). The inhibitory effect
of oral protein on C-22 stimulation of GIP secretion is likely caused by
receptor desensitization caused by exposure of GIP cells in the proximal
small intestine to high concentrations of absorbed aromatic amino acidan open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 7: Effects of chronic in-feed treatment with synthetic GPR142 agonist on metabolic functions of DIO mice. Effects on body weight (A), food intake (B), energy
expenditure (C), daily energy balance (D), locomotor activity (E), RER (F), glucose oxidation (G), OGTT (tested at week 4 from the start of treatment) (H), fasting insulin (I) and
insulin tolerance (J) (tested at weeks 5 from the start of treatment) of DIO mice after feed administration of vehicle or C-22 (~30 mg/kg/day). N ¼ 7e8 in each group. (K)
Pancreatic content of insulin, glucagon, tGLP-1 (n ¼ 7e8 in each group) and (L) duodenal tGLP-1 (n ¼ 6e7 in each group) from acid-ethanol extraction after treatment
intervention for 6 weeks. In (B,E,G) data was averaged for light and dark phases. (C,F) represent 36 h proﬁle for energy expenditure (C) and RER (F). Black horizontal bar
represents lights-off (active) period during a 12:12 h light/dark cycle. Signiﬁcant difference indicated on graph was calculated as mean for light and dark phases. Data in (H,J)
*p < 0.05, **p < 0.01, ***p < 0.005 vehicle vs C-22; determined as two-way ANOVA with Sidak’s post-hoc test.and oligopeptide metabolites from the protein. However, the fact that
glucose also blocks the ability of the GPR142 agonist to further stimulate
GIP secretion is more difﬁcult to explain, since it was also observed with
lower glucose doses, which only stimulated GIP partly. Perhaps the GIP
cell is specially tuned in respect of dietary metabolite sensing?
In relation to pancreatic islets, it was generally assumed that GPR142
would be a b-cell receptor as the receptor originally was discovered to
be almost exclusively expressed in islets [2]. This notion was under-
scored by the glucose-dependent strong stimulatory effect on insulin
secretion of the ﬁrst GPR142 agonists, including C-22 [5,6], which we
could conﬁrm in the present study. However, as also demonstrated here
and as recently shown also by in situ hybridization [8], GPR142 is in fact
even more highly expressed in a-cells, which also is evident from single
cell data analysis [25]. Importantly, the GPR142 agonist is a very
powerful stimulator of glucagon secretion which even works at high
glucose level that normally suppresses glucagon secretion (Figure 3G,J).MOLECULAR METABOLISM 19 (2019) 49e64  2018 Published by Elsevier GmbH. This is an open acces
www.molecularmetabolism.comVery recently, it was proposed that GPR142-induced increase in
circulating levels of GLP-1 also originated from the a-cells because of an
increase in expression of the peptide precursor converting enzyme PC1/
3 [9]. The amount of GLP-1 stored in islet cells increased to one third of
the amount of glucagon upon a four-day treatment of islet cells with the
GPR142 agonist. It was also proposed that a-cell-derived GLP-1 through
a paracrine mechanism could be responsible for an observed b-cell
proliferative effect of the GPR142 agonist [9]. This would implicate that
chronic treatment with a GPR142 agonist should increase production of
GLP-1 in the islets, which would have a beneﬁcial insulinotropic effect.
However, in the present study we did not observe any increase in the
amount of GLP-1 or insulin stored in the pancreas from DIO mice treated
chronically with C-22.
Concerning GPR142-induced increase in circulating GLP-1, it is still
possible that intestinally derived GLP-1 is in play as the GPR142 agonist
did stimulate GLP-1 secretion at least from intestinal organoids.s article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 61
Original ArticleHowever, the expression level of GPR142 in intestinal GLP-1 cells is
relatively low and the efﬁcacy of the GPR142 agonist was also relatively
low as compared to for example a TGR5 receptor agonist.
4.2. Acute metabolic effects of GPR142 agonists
Despite stimulating CCK and GLP-1, C-22 did not decrease food intake
in the present study but did decrease gastric emptying rather strongly
even on top of the inhibitory effect of an oral protein challenge. This
inhibitory effect of the GPR142 agonist on gastric emptying, which
probably mainly is mediated by CCK, could relate to a possible
physiological role of GPR142 being one of several sensors of dietary
protein ingestion as gastric emptying plays an important role in con-
trolling delivery of protein for further digestion and absorption in the
small intestine. Interestingly, gastric emptying is reduced by oral
tryptophan in humans [36,37], which very well could be mediated
through GPR142. The effect on gastric emptying should be taken into
account when evaluating the therapeutic potential of GPR142 agonist.
The GPR142 agonist improved glucose tolerance rather dramatically
even in lean, normal animals. Thus, although GPR142 stimulates both
insulin and glucagon efﬁciently it is the insulin effect which dominates
at least in the OGTT situation. There were no signs of GPR142 agonist
resistance in DIO mice, as the agonist stimulated hormone secretion
and improved glucose tolerance very efﬁciently also in these animals.
This was also observed in Zucker Fatty rats. However, when the
glucose uptake was directly studied the two glucoregulatory hormones
leveled out each other’s effect in respect of balancing blood glucose,
i.e. the strong insulin mediated increase in glucose uptake in muscle
and fat as determined by labeled 2-deoxyglucose was counteracted by
a conceivably glucagon-mediated glycogenolytic effect on the liver
resulting in no change in total blood glucose levels. All of these effects
were also observed in DIO mice. In respect of overall substrate pref-
erence, the GPR142 agonist induced an increase in carbohydrate
burning as indicated in an increase in RER observed both in the acute
and the chronic setting.
4.3. Effects of chronic treatment with a GPR142 agonist on
metabolic functions
Although C-22 has a great bioavailability and consequently can be
administered as part of the diet, its plasma clearance is, unfortu-
nately, rather quick [5,7], which means that the compound is no
longer present in therapeutic concentrations in experiments, which
are performed after fasting, for example OGTT; this should be
considered when interpreting results from the chronically treated
animals. Thus, we only observe a rather limited effect on the in-
cremental glucose excursions in the chronically GPR142 treated DIO
animals as compared to the large improvements in glucose tolerance
observed after acute administration of C-22 in the DIO animals.
Importantly however, we do observe a signiﬁcant decrease in fasting
basal glucose in the chronically treated animals, which according to
the PK of the compound is not a result of a direct stimulatory effect
of the compound on insulin secretion, because the compound is no
longer present when the samples are taken. Conceivably the
decrease in basal glucose is instead a result of the increase in in-
sulin sensitivity, which is induced in these animals upon chronic
treatment with the GPR142 agonist. The increase in insulin sensi-
tivity is also observed under fasting conditions in which the com-
pound is no longer present (Figure 7J). The basis for the surprising
increase in insulin sensitivity in these highly insulin resistant animals
is still unclear and requires further studies. It may be noted that
GPR142 is not expressed consistently on immune cells (unpublished
data), so it is unlikely that an anti-inﬂammatory effect is involved.62 MOLECULAR METABOLISM 19 (2019) 49e64  2018 Published by Elsevier GmbH. This isEnergy expenditure was increased in DIO animals upon chronic
treatment with the GPR142 agonist. This was also rather surprising, as
no effect on energy expenditure was observed in the acute setting at
least not in lean animals. This stimulatory effect on energy expenditure
in DIO animals, which was most prominent in the dark phase, was
measured in the TSE system, in which the animals were freely eating
the C-22-containing food and therefore exposed to the compound
during the measurements. Consequently the GPR142 effect on energy
expenditure could be a result of the increased glucagon levels [38].
Importantly, there was no effect on body weight in these very obese
DIO animals despite the observed increase in energy expenditure,
which possibly could be related to the nominal, but not signiﬁcant
increase in food intake.
It could be speculated that a GPR142 agonist with a better PK, allowing
for constant drug exposure, would provide both the observed improved
insulin sensitivity and the robust increase in glucose tolerance
observed in the acute setting combined with an increase in energy
expenditure. Such a compound could be combined with a GLP-1
mimetic, which on top of its other beneﬁcial effects would provide
an additional robust anorectic effect.
4.4. Is GPR142 a physiological sensor of dietary protein?
Amino acid homeostasis is tightly regulated through a balance between
protein synthesis and degradation. The pool of systemic free amino
acids is derived from dietary protein, de novo synthesized amino acids,
and amino acids generated from autophagy (reviewed in [39]). Dietary
intake of protein will affect a series of processes throughout the body,
including increased amino acid uptake, increased protein synthesis,
decreased protein degradation, and increased ureagenesis. Hormonal
and neuronal mechanisms including a balance between insulin and
glucagon effects are critical in controlling these processes. Accordingly,
dietary protein and free amino acids are known to act as robust stim-
ulators of insulin and glucagon as well as most gut hormones.
Several GPCRs are already known to function as sensors of amino
acids, e.g., the calcium sensing receptor (CasR), taste receptors T1R1/
T1R3, and metabotropic glutamate receptors. However, among these
only CasR is expressed in a manner which would implicate it as a
sensor of dietary protein in the GI-tract, which is supported by a
number of functional studies [40e45]. The expression pattern and
functional properties of GPR142 would indicate that also this receptor
functions as a sensor of dietary proteins through aromatic amino acid
and oligopeptide metabolites. The observation in the present study that
GPR142 is responsible for the stimulatory effect of orally administered
L-Trp on gut and pancreatic hormones would support this notion.
However, the amount L-Trp administered was far from physiological
and our results with an oral protein challenge clearly indicate that
GPR142 is not required for sensing of dietary proteins by the enter-
opancreatic endocrine cells as normal hormone response to the protein
was observed in GPR142 KO animals (Figure 2F). As at least CasR and
possibly other receptors are also likely involved in sensing of dietary
proteins it is expected that compensatory mechanisms could have
arisen in the GPR142 deﬁcient mice. Importantly, GPR142 has both the
expression pattern and functional properties to function as a physio-
logical sensor of dietary proteins, including the ability to stimulate both
insulin and glucagon and strongly stimulate GIP, which, in contrast to
GLP-1, stimulates both insulin and glucagon. The balance between
insulin and glucagon is important both for postprandial amino acid
metabolism and to avoid hypoglycemia due to insulin stimulation [46].
More studies including use of pharmacological antagonists and
inducible knock out animal models will be required to determine the
possible physiological role of GPR142 as a sensor of dietary proteins.an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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4.5. Concluding remarks
Based on the present and recently published studies, it is clear that
GPR142 is not just another insulin secretagogue receptor. GPR142
appears to have a role as a sensor of aromatic essential amino acids
controlling the secretion of in particular GIP but also CCK and GLP-1 in
the GI-tract and both insulin and glucagon and perhaps GLP-1 in the
pancreas. In the present study, we have focused on effects on glucose
metabolism; however, future studies should probably focus more on
the potential physiological role of GPR142 in amino acid metabolism,
i.e. indirectly through its balanced control of insulin and glucagon
secretion. The pharmacological potential of GPR142 is also much more
interesting than just increasing insulin secretion and improving glucose
tolerance. Our study indicates that chronic GPR142 agonist treatment
may increase insulin sensitivity and energy expenditure through
mechanisms which needs to be further determined.
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